Onconova stock falls 10% on preclinical data for lymphoma drug

seekingalpha2023-12-12

Shares of Onconova Therapeutics (NASDAQ:ONTX) fell 10% early Tuesday after the biotech company presented preclinical data for its drug candidate narazaciblib in the treatment of BTKi-resistant mantle ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2390437553?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/478530138/image_478530138.jpg","is_english":true,"pubTime":"2023-12-12 22:43","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2390437553","market":"us","top_or_hot":-1,"title":"Onconova stock falls 10% on preclinical data for lymphoma drug","media":"seekingalpha","content":"<div>\n<p>Shares of Onconova Therapeutics (NASDAQ:ONTX) fell 10% early Tuesday after the biotech company presented preclinical data for its drug candidate narazaciblib in the treatment of BTKi-resistant mantle ...</p>\n\n<a href=\"https://seekingalpha.com/news/4045509-onconova-stock-falls-on-preclinical-data-for-lymphoma-drug\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Onconova stock falls 10% on preclinical data for lymphoma drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOnconova stock falls 10% on preclinical data for lymphoma drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-12 22:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4045509-onconova-stock-falls-on-preclinical-data-for-lymphoma-drug><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Onconova Therapeutics (NASDAQ:ONTX) fell 10% early Tuesday after the biotech company presented preclinical data for its drug candidate narazaciblib in the treatment of BTKi-resistant mantle ...</p>\n\n<a href=\"https://seekingalpha.com/news/4045509-onconova-stock-falls-on-preclinical-data-for-lymphoma-drug\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://seekingalpha.com/news/4045509-onconova-stock-falls-on-preclinical-data-for-lymphoma-drug","article_id":"2390437553","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/478530138/image_478530138.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2390437553","pubTimestamp":1702392215,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Onconova Therapeutics  fell 10% early Tuesday after the biotech company presented preclinical data for its drug candidate narazaciblib in the treatment of BTKi-resistant mantle cell lymphoma.  Onconova presented the data on Monday at the American Society of Hematology meeting in San Diego. The company said it is planning to define the recommended Phase 2 dose and prepare for registrational trials for the product in the treatment of low grade endometrioid endometrial carcinoma, with an update planned for the first half of 2024.  More on Onconova Therapeutics  Onconova Therapeutics, Inc.  Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Onconova Therapeutics Historical earnings data for Onconova Therapeutics Financial information for Onconova Therapeutics","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药"},"translate_title":"Onconova股票因淋巴瘤药物临床前数据下跌10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONTX":1},"content_text":"Shares of Onconova Therapeutics (NASDAQ:ONTX) fell 10% early Tuesday after the biotech company presented preclinical data for its drug candidate narazaciblib in the treatment of BTKi-resistant mantle cell lymphoma.  Onconova presented the data on Monday at the American Society of Hematology meeting in San Diego. The company said it is planning to define the recommended Phase 2 dose and prepare for registrational trials for the product in the treatment of low grade endometrioid endometrial carcinoma, with an update planned for the first half of 2024.  More on Onconova Therapeutics  Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Onconova Therapeutics Historical earnings data for Onconova Therapeutics Financial information for Onconova Therapeutics","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2390437553"}